| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439304 | European Journal of Cancer | 2018 | 10 Pages |
Abstract
Recurrent DCIS or invasive cancer is uncommon after screen-detected DCIS. Both RT and endocrine therapy were associated with a reduction in further events but not with breast cancer mortality within 5 years of diagnosis. Further research to identify biomarkers of recurrence risk, particularly as invasive disease, is indicated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alastair M. Thompson, Karen Clements, Shan Cheung, Sarah E. Pinder, Gill Lawrence, Elinor Sawyer, Olive Kearins, Graham R. Ball, Ian Tomlinson, Andrew Hanby, Jeremy St J. Thomas, Anthony J. Maxwell, Matthew G. Wallis, David J. Dodwell,